Author:
Dickinson James,Lewand Michaelene,Sawamoto Taiji,Krauwinkel Walter,Schaddelee Marloes,Keirns James,Kerbusch Virginie,Moy Selina,Meijer John,Kowalski Donna,Morton Richard,Lasseter Kenneth,Riff Dennis,Kupčová Viera,van Gelderen Marcel
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference26 articles.
1. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–7.
2. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.
4. Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816.
5. Khullar V, Amarenco G, Angulo J, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European–Australian Phase 3 trial. Eur Urol. Accepted.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献